

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known Application Number 09/368,866 Filing Date 08/05/99 First Named Inventor Llinas-Brunet, M. et al Group Art Unit 1613 Examiner Name Attorney Docket Number 13/068	
Sheet	1	of	2		

[illegible][illegible]

Examiner Signature	<i>J. Smock</i>	Date Considered	11-29-00
-----------------------	-----------------	--------------------	----------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐



PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/368,866		
		Filing Date	08/05/99		
		First Named Inventor	Llinas-Brunet, M. et al		
		Group Art Unit	1613		
		Examiner Name			
Sheet	2	of	2	Attorney Docket Number	13/068

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JCB		GAUCHER, Et Al; "Palladium (0) Catalyzed Tandem Alkylation and SN ¹ Cyclization of 1,4-Dichlorobut-2-ene by the N-(Diphenylmethylene) acetonitrile. A Stereoselective Synthesis of 1-Aminocyclo- propanecarboxylic Acids"; Tetrahedron Letters, vol 36, No.17, Pg. 2979-2982; 1995	
		FLICHE, Et Al; "Enantioselective synthesis of (1R,2S) and (1S,2S) dehydrocoronamic acids", Synthetic Communications; Vol. 24, No. 20, 1994, Pg. 2873-2876	
		CHEN, Et Al; "Chirally selective hydrolysis of D, L amino acid esters by alkaline protease"; J. Chem, Soc. Chem. Commun., Vol. 20, 1986, Pg. 1514-1516	
		CHEN, Et Al; "Kinetic resolution of esters of amino acids in t-butanol containing 5% water catalyzed by a stable industrial alkaline protease"; Chirality, Vol. 6, 1994, Pg 572-576	
		LLINAS-BRUNET, M., Et Al; "Peptide-based inhibitors of the hepatitis C virus serine protease", Bioorganic & Medicinal Chemistry Letters, Vol. 8, No. 13, Pg 1713-1718; 1998	
		GERSHONOV Et Al; "1-Aminocyclobutanecarboxylic acid derivatives as novel structural elements in bioactive peptides: application to tuftsin analogs"; Journal of Medicinal Chemistry, Vol 39, No. 24, 1996, Pg 4833-4843	
		OGAWA, TOMOHISA ET AL: "2,3-METHANOPHENYLALANINE AND.ALPHA., .BETA.-DEHYDROPHENYLALANINE DERIVATIVES AS CHYMOTRYPSIN INHIBITOR"; PEPT. CHEM. (1990), Vol.27; Pg 379-382.	

Examiner Signature		Date Considered	11-29-00
-----------------------	--	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.